Skip to main content

Table 3 Functional outcome and postoperative complications in all three groups

From: Efficacy of low-dose intra-articular tranexamic acid in total knee replacement; a prospective triple-blinded randomized controlled trial

 

Control group

TXA 250 mg

TXA 500 mg

p-value

 

(nā€‰=ā€‰45)

(nā€‰=ā€‰45)

(nā€‰=ā€‰45)

 

WOMAC scoreāœ

ā€ƒā€ƒā€ƒā€ƒā€ƒ 3 months

36.7 (8.2)**

35.8 (7.6)**

35.5 (7.2)**

0.42

ā€ƒā€ƒā€ƒā€ƒā€ƒ 6 months

25.4 (6.0)**

23.1 (6.5)**

23.5 (6.6)**

 

ā€ƒā€ƒā€ƒā€ƒā€ƒ 1 year

15.5 (6.6)**

15.1 (6.2)**

14.5 (7.1)**

 

ā€ƒā€ƒā€ƒā€ƒā€ƒ p-value within group

< 0.001**

< 0.001**

< 0.001**

 

Knee society knee scoreāœ

ā€ƒā€ƒā€ƒā€ƒā€ƒ 3 months

121.7 (10.2)**

121.1 (10.1)**

123.3 (9.1)**

0.91

ā€ƒā€ƒā€ƒā€ƒā€ƒ 6 months

141.0 (11.5)**

141.2 (9.4)**

140.0 (8.9)**

 

ā€ƒā€ƒā€ƒā€ƒā€ƒ 1 year

148.9 (10.1)**

151.2 (9.1)**

150.9 (9.3)**

 

ā€ƒā€ƒā€ƒā€ƒā€ƒ p-value within group

< 0.001**

< 0.001**

< 0.001**

 

Complicationsā—†

ā€ƒā€ƒā€ƒā€ƒā€ƒ Re-clamp

6 (13%)

1 (2%)

0 (0%)*b

0.01

ā€ƒā€ƒā€ƒā€ƒā€ƒ Re-dressing

3 (7%)

0 (0%)*a

0 (0%)*b

0.05

ā€ƒā€ƒā€ƒā€ƒā€ƒ VTE

4 (9%)

1 (2%)

2 (4%)

0.35

ā€ƒā€ƒā€ƒā€ƒā€ƒ Congestive heart failure

0 (0%)

1 (2%)

0 (0%)

1.00

  1. āœā€‰=ā€‰The values were presented as mean (standard deviation), ā—†ā€‰=ā€‰The values were presented as number of patients having that condition (percentage of this group), **; p-value between timeā€‰<ā€‰0.001, *; pā€‰<ā€‰0.05.
  2. aā€‰=ā€‰comparison between control and TXA-250 group with pā€‰<ā€‰0.05.
  3. bā€‰=ā€‰comparison between control and TXA-500 group with pā€‰<ā€‰0.05.